News Reader.info

Neuroendocrine liver metastases often require multiple modes of treatment to attain disease control, which can utilize various forms of radiolabelled agents either delivered systemically or

preferentially towards the liver. A recent trial suggested both safety and efficacy of a novel approach of combining the two to provide a radiation ‘boost’ to hepatic deposits. Access

through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other

Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online

access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which

are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Frilling, A. et al.

Recommendations for management of patients with neuroendocrine liver metastases. _Lancet Oncol._ 15, e8–21 (2014). Article  Google Scholar  * Dasari, A. et al. Trends in the incidence,

prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. _JAMA Oncol._ 3, 1335–1342 (2017). Article  Google Scholar  * Chen, J. X. et al. Embolotherapy

for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. _Cardiovasc. Intervent. Radiol._ 40, 69–80 (2017). Article  Google

Scholar  * Kratochwil, C. et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. _Endocr. Relat. Cancer_ 18, 595–602 (2011).

Article  CAS  Google Scholar  * Kennedy, A. et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus

Conference. _HPB_ 17, 29–37 (2015). Article  Google Scholar  * Frilling, A. et al. Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series,

systematic review and meta-analysis. _HPB_ 21, 773–783 (2019). Article  Google Scholar  * Braat, A. J. A. T. et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in

patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. _Lancet Oncol._ 21, 561–570 (2020). Article  CAS  Google Scholar  *

Strosberg, J. et al. Phase 3 Trial of 177Lu-dotatate for midgut neuroendocrine tumors. _N. Engl. J. Med._ 376, 125–135 (2017). Article  CAS  Google Scholar  * Pavel, M. et al. ENETS

consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site.

_Neuroendocrinology_ 103, 172–185 (2016). Article  CAS  Google Scholar  * Kennedy, A. et al. Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with

systemic anticancer agents: Expert consensus. _J. Gastrointest. Oncol._ 8, 1079–1099 (2017). Article  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS *

Department of Surgery & Cancer, Imperial College London, London, UK Andrea Frilling & Ashley Kieran Clift * NHS Nightingale Hospital London, London, UK Ashley Kieran Clift Authors *

Andrea Frilling View author publications You can also search for this author inPubMed Google Scholar * Ashley Kieran Clift View author publications You can also search for this author

inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Andrea Frilling. ETHICS DECLARATIONS COMPETING INTERESTS A.F. reports receiving speaker honoraria from SIRTEX. A.K.C. declares

no competing interests. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Frilling, A., Clift, A.K. Combining radiolabelled therapies for neuroendocrine

neoplasms. _Nat Rev Endocrinol_ 16, 347–348 (2020). https://doi.org/10.1038/s41574-020-0367-3 Download citation * Published: 07 May 2020 * Issue Date: July 2020 * DOI:

https://doi.org/10.1038/s41574-020-0367-3 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative